ProCE Banner Activity

CME

Key Studies in Myeloma: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting

Conference Coverage
Text Module

Expert faculty review and share their insights and perspectives on key findings in multiple myeloma from ASH 2020.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 22, 2021

Expiration: March 21, 2022

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with malignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with multiple myeloma
  • Plan therapeutic approaches for patients with multiple myeloma considering the latest data presented at ASH 2020
  • Discuss new data on novel agents and therapeutic approaches for patients with multiple myeloma
  • Consider how new trial findings might affect treatment of patients with multiple myeloma in the future

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has ownership and interest in TG Therapeutics and has received funds for research support from Bristol-Myers Squibb, Janssen, and Takeda and consulting fees from AbbVie, Amgen, Bristol- Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Takeda.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 22, 2021, through March 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with multiple myeloma.